Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BliNK Therapeutics Ltd.

Division of BliNK Biomedical SAS

Latest From McNeil Consumer Healthcare

Dermatology OTC Switches Loom Next For Consumer Health Growth

Dermatology OTC switch products for acne, eczema and psoriasis are likely to emerge, says Kline analyst Laura Mahecha. Switches, the return of recalled OTC brands and market consolidation drove a 4.2% increase for the US consumer health market in 2015.

Prescription To Otc Switch Dermatology

Prelief Supplement Scores OTC Drug Comparison, But Misses On Acid Removal – NAD

DSE Healthcare substantiates online claims that the Prelief supplement “does not predispose” to problems associated with use of PPIs and beta blockers, NAD says, but advises the firm to discontinue broad acid-removal and symptom-cessation claims.

United States Advertising, Marketing & Sales

In Most Consumers' OTC Pain Relief Decisions, Safety Missing As A Factor

Most US consumers choose pain relievers based on speed and efficacy instead of factors critical to safe use – age, health conditions and use of other OTCs and drugs – according to a survey supported by J&J/McNeil.

Consumer Drug Safety

GSK's Flonase Sensimist (Veramyst) Switches Name On Way To OTC

GSK gains approval of sNDA for Rx Veramyst (fluticasone furoate/spray) to be marketed OTC as Flonase Sensimist, an extension of the Flonase Allergy Relief.

Prescription To Otc Switch Consumer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • BliNK Biomedical SAS
  • Senior Management
  • Contact Info
  • BliNK Therapeutics Ltd.
    Phone: 20 3469 6300
    c/o Cancer Research Technology
    407 St John St.
    London, EC1V 4AD